Form 4: Elevation Oncology Director Steven Elms Granted Stock Options

Director Steven Elms of Elevation Oncology, Inc. (ELEV) was granted stock options for 35,000 shares on June 13, 2024, vesting one year from the grant date.

Summary

• Steven Elms, a director of Elevation Oncology, Inc., was granted stock options to purchase 35,000 shares of common stock on June 13, 2024.
• The exercise price of the options is $3.35 per share.
• The options vest 100% on the one-year anniversary of the grant date, contingent upon Mr. Elms' continued service to the Issuer.
• Mr. Elms is an employee of Aisling Capital, and according to Aisling Capital's policies, he does not have any right to the Issuer's securities issued as part of his service on the Board, and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued.
• A Power of Attorney was executed on June 17, 2024, granting Joseph Ferra, Tammy Furlong, and Robert Yang the authority to file reports on Mr. Elms' behalf.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative. The sentiment is neutral.

Positives

• The granting of stock options to a director aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize directors and align their interests with the long-term success of the company. This is a standard form 4 filing related to the grant.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotechnology industry.
• The vesting schedule of one year is fairly standard.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholder sentiment as it aligns the director's interests with the company's success.

Key Dates